Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4462 USD | -7.02% | -11.75% | -68.35% |
Apr. 01 | BTIG Research Downgrades P3 Health Partners to Neutral From Buy | MT |
Mar. 28 | Transcript : P3 Health Partners Inc., Q4 2023 Earnings Call, Mar 28, 2024 |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.08 for the 2024 fiscal year.
- The company appears to be poorly valued given its net asset value.
- The company has a low valuation given the cash flows generated by its activity.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-68.35% | 53.28M | - | ||
+1.51% | 42.75B | B | ||
+49.22% | 41.61B | A | ||
+8.57% | 41.34B | B- | ||
-12.36% | 26.59B | C | ||
+8.92% | 25.49B | B- | ||
-25.13% | 18.12B | B | ||
+29.17% | 12.24B | C+ | ||
-3.12% | 11.76B | C+ | ||
+6.35% | 11B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- PIII Stock
- Ratings P3 Health Partners Inc.